Subscribe
Your AI-Trained Oncology Knowledge Connection!
The study evaluated the use of pembrolizumab compared with brentuximab vedotin in patients with relapsed or refractory classic Hodgkin Lymphoma.
FDA Lifts Partial Clinical Hold on TELLOMAK Phase 2 Trial of Lacutamab
FDA Approves Oral Selinexor for R/R DLBCL
FDA Approves Tazemetostat for 2 Follicular Lymphoma Indications
Caron A. Jacobson, MD, on the Findings of the Phase 2 ZUMA-5 Study
Sapna Patel, MD; Jack W. Erter III, MD, MMHC
October 15, 2025
Yana G. Najjar, MD; Rakesh Bagai, MD
Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS
Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD
October 26, 2025
Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH
Sapna Patel, MD; Rakesh Bagai, MD
Yana G. Najjar, MD; Deepa Jagtap, MD
Yana G. Najjar, MD; Anand Patel, MD
November 15, 2025
Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD
Richard S. Finn, MD; Anthony B. El-Khoueiry, MD; Pierre Gholam, MD; Lipika Goyal, MD
Kathleen N. Moore, MD, MS, FASCO; Susana Banerjee, MBBS, MA, FRCP, PhD; David M. O’Malley, MD; Ritu Salani, MD, MBA
Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD
Mark G. Kris, MD; Justin Gainor, MD; Isabel Preeshagul, DO, MBS; Helena A. Yu, MD
Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA
Kathleen N. Moore, MD, MS, FASCO; David M. O’Malley, MD